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Available online xxxxGenetic counseling for cystic ﬁbrosis (CF) is challenged by intricatemolecularmechanisms, complex phenotypes,
and psychosocial needs. CFTR variant interpretation has become critical; this manuscript examines variant no-
menclature and classes, as well as opportunities and challenges posed by genetic technologies and genotype-
directed therapies. With post-graduate training in medical genetics and counseling, genetic counselors educate
patients and families, facilitate testing and interpretation, and help integrate genetic information into diagnosis
and treatment. They support families, ranging from carrier couples or new parents, to children understanding
their disease, to adults with CF contemplating reproduction. The changing face of CF increasingly highlights the
critical importance of genetic information to patients and their families. Genetic counselors are uniquely poised
to translate this information indiagnostics andpersonalized care. Genetic counselors straddlemolecular and clin-
ical realms, helping patients adapt, plan, and gain access to appropriate therapies.
© 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords:
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Table 1
Terminology [3–7].
Term Deﬁnition
Cystic ﬁbrosis (CF) • A CF diagnosis can be made in individuals
who have at least one feature/ﬁnding from
both categories below:
• A: CLINICAL FEATURES B: LABORATORY
FINDINGS
• -Clinical symptoms consistent with CF -
Sweat chloride ≥60 mmol/L
• -A positive newborn screen−2 CF-causing
variants in trans
• -Family history of CF -Abnormal nasal
potential difference
CFTR-related metabolic
syndrome (CRMS)/
cystic ﬁbrosis screen positive,
inconclusive diagnosis (CFSPID)
CRMS (United States) and CFSPID (other
countries) are terms applied to infants with a
positive newborn screen for CF who do not
have clinical features of CF. Individuals with
CRMS/CFSPID must have a positive newborn
screen and either:
- a sweat chloride b30 mmol/L and 2 CFTR
variants where at least 1 has unclear
phenotypic consequences OR
- an intermediate sweat chloride (30–59
mmol/L) and 1 or 0 CF-causing mutations
CFTR-related disorder A monosystem clinical entity (e.g. CBAVD,
pancreatitis, bronchiectasis) associated with
CFTR dysfunction that does not fulﬁll the
diagnostic criteria for CF
CFTR variant Differences from the accepted or reference
DNA sequence of the CFTR gene; may or may
not be harmful
CFTRmutation In some instances, the term mutation has been
used interchangeably with variant to describe
any change from the reference DNA sequence.
More correctly, mutation refers only to
pathogenic sequence variations. Recently,
variant has become the preferred term for all
sequence variations with disease liability
designated.
CF-causing variant/ causative
variant
A variant expected to cause CF when present in
trans with another CF-causing variant
Variant of varying clinical
consequence (VCC)
A variant that may or may not result in CF
when present in trans with a CF-causing
variant
Non CF-causing variant A variant not expected to result in CF when
present in trans with a CF-causing variant.
Most individuals with this type of variant
combination will be healthy. A small number
of individuals may develop mild symptoms or
be diagnosed with a CFTR-related disorder, but
symptoms are not expected to meet the
deﬁnition of CF.
Variant of uncertain signiﬁcance At this time, it is uncertain whether the variant
is disease-causing or not
Complex allele A single CFTR gene containing more than one
variant; Several well-known examples
include: c.1727G N G and c.2002C N T [G576A
and R668C], c.1521_1523delCTT and c.3080 T N
C [F508del and I1027T], and c.220C N T and
c.3808G N A [R74W and D1270N]
Cis conﬁguration The occurrence of more than one variant
within the same CFTR gene, i.e. a complex
allele with both variants inherited from one
parent
Trans conﬁguration The occurrence of bi-allelic variants; a CFTR
variant was inherited from each parent. CF
occurs due to causative variants in trans
conﬁguration
Genetic counselor A professional with post-graduate training in
medical genetics and counseling to interpret
genetic test results and provide personalized
patient guidance and support
Genetic counseling The process of helping people understand and
adapt to genetic contributions to disease,
including impacts on the individual and family
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Cystic ﬁbrosis (CF) is an autosomal recessive condition caused by
variants in the cystic ﬁbrosis transmembrane conductance regulator
(CFTR) gene. Frequently used as a basic genetics teaching example,
counseling for CF is complex despite apparent genetic simplicity. Varied
penetrance of CFTR variants makes phenotypic prediction challenging,
and emergence of therapies addressing the underlying genetic defect
are changing the clinical landscape. There has also been a change in
nomenclature: healthcare professionals are familiar with the term mu-
tation, which is more accurately termed a causative variant (the termi-
nology used in this manuscript). In addition, there has been a move
from the legacy system of describing variants by their impact on the
protein product to the Human Genome Variation Society (HGVS) sys-
tem, in which a variant is described by its change to the genetic code.
In this paper we refer to variants ﬁrst by HGVS name (also known as
cDNA name) with legacy name in brackets, which is used thereafter.
Terminology is reviewed in Table 1.
Cystic ﬁbrosis is a multifaceted condition with wide clinical variabil-
ity, hundreds of causative CFTR variants, and genotype-based treat-
ments. The variant c.350GNA [R117H] is relatively common and an
example of a variant resulting in varied penetrance, ranging from no
phenotypic impact to CFTR-related disorder (CFTR-RD) to CF. While
R117H is an extreme example, varied clinical impact is a feature of all
CFTR variants. Collaborative resources, including Clinical and Functional
Translation of CFTR (CFTR2) and CFTR-France, have been developed to
collect and share genotype and phenotype information among re-
searchers, clinicians, and patients.
The role of the genetic counselor spans all ages of CF care from pre-
conception or prenatal testing, to newborn screening (NBS), and to sup-
port with treatment and decision-making later in life. The genetic
counselor requires a wide skillset to place complex genetic principles
in both medical and psychosocial frameworks [1,2].
Expert genomic knowledge is critical to translate genetic test results
to improved care. Genetic counselors are healthcare professionals with
post-graduate training inmedical genetics and counseling. They provide
information and support needed to understand genetic results and fa-
milial implications, adjust to a diagnosis, and make decisions that are
medically sound yet suited to the patient or family's goals [1,2].
In this review, we describe the issues around CFTR gene testing and
classiﬁcation and the impact of results at different ages, reﬂecting on
distinct roles of the genetic counselor at these times.
2. CFTR testing and interpretation
Reﬂecting increased ability to interrogate and interpret DNA
changes, the CF diagnostic algorithm now incorporates CFTRmolecular
testing [4]. Identiﬁcation of two causative variants is diagnostic for CF,
even in the absence of a diagnostic sweat chloride, though a sweat chlo-
ride test (SCT) is still necessary [4]. Multiple testing methodologies are
widely available and are summarized in Table 2. Genetic counselors
are well-poised to evaluate test utility, including considerations of pa-
tient ethnicity, clinical presentation, cost, insurance coverage, turn-
around time, and intended use of results. Studies in other conditions
have found that genetic counselor involvement in molecular test selec-
tion signiﬁcantly reduces errors and cost [2,8].
A genetic counselor is valuable for interpreting and explaining re-
sults, both straightforward and complex. Complex examples include sit-
uations in which more than one (in carrier screening) or two (in
diagnostic testing) variants are identiﬁed, assessment of an at-risk
fetus, interpretation of variants affected by in cis changes (e.g. R117H
and polyT), and scenarios in which disease liability of a variant is un-
known or variable. Follow-up testing, evaluation, and counseling for
the patient and family are often warranted. Case 1 (Table 3) illustrates
the importance of incorporating genotype into diagnosis and treatment,
even in atypical presentation.Please cite this article as: K.E. Foil, A. Powers, K.S. Raraigh, et al., The increasing challenge of genetic counseling for cystic ﬁbrosis, Journal of Cystic
Fibrosis, https://doi.org/10.1016/j.jcf.2018.11.014
Table 2
Types of CFTR genetic testing.
Type of CFTR
genetic test
Capabilities and limitations Most appropriate for
CFTR variant
panel
Detects speciﬁc variants on
the panel and no others, often
the most common variants in
the Caucasian population;
Widely variable detection rate
dependent on ethnic
background and panel
makeup
Routine carrier screening for
those with no family history of
CF; patients with a clear CF
diagnosis who are Ashkenazi
Jewish or European Caucasian;
commonly used genetic test-
ing in newborn screening
algorithms
Traditional
sequencing
(i.e. Sanger
sequencing)
Detects all sequence changes
in exons and intron-exon
junctions of CFTR; does not
detect large deletions or
duplications
Patients with a CF diagnosis
who are not Ashkenazi Jewish
or European Caucasian, or
who have fewer than two
mutations identiﬁed from
panel testing; may be utilized
as a carrier screen when one
partner is affected or a known
carrier especially in the setting
of non-Caucasian ethnicity.
Deletion /
duplication
analysis
Detects large deletions and
duplications involving all or
part of exons in CFTR; does not
detect sequence changes
Patients with a CF diagnosis
who have had fewer than two
CF-causing variants identiﬁed
after CFTR sequencing
Next-generation
sequencing
Detects sequence changes in
exons and intron-exon
junctions of CFTR; does not
detect large deletions or
duplications without speciﬁc
further analysis by laboratory
(some - but not all - labs offer
this)
Patients with a CF diagnosis
who are not Ashkenazi Jewish
or European Caucasian, or
who have fewer than two CF--
causing variants identiﬁed
from panel testing; may be
utilized as a carrier screen
when one partner is affected
or a known carrier especially
in the setting of non--
Caucasian ethnicity; may be
utilized in screening algo-
rithms if a multi-step reveal of
results is required
Targeted familial
variant testing
Detects only one or two
speciﬁc variants that have
been previously identiﬁed in a
family
Determines presence or
absence of speciﬁc variant(s)
in close relatives of a patient
or carrier; useful for parent or
sibling follow-up testing
Table 3
Cases.
Case 1. AF is a 13-year-old competitive
dancer who was healthy until age 10,
when she developed a chronic cough
after viral illness. Standard asthma
treatments failed and symptoms
worsened. Allergy and immunology
workups were negative. Over the next
two years chest radiographs
progressed from peri-hilar inﬁltrates
to bronchiectasis, and she was
referred to pulmonology. Testing
revealed intermediate SCT at 37
mmol/L and two causative CFTR
variants: c.3718-2477C N T [3849 +
10kbC N T] and c.1680-886A N G [1811
+ 1634A N G]. In further evaluation
she was pancreatic sufﬁcient with one
prior episode of pancreatitis, and
respiratory cultures were positive for
Staphylococcus aureus. Several
CF-speciﬁc respiratory treatments
were initiated with marked
improvement in symptoms. She has
recently started tezacaftor/ivacaftor
combination therapy.
Case 2. TS is a 4-week-old male deemed
a carrier of c.1521_1523delCTT
[F508del] following positive NBS and
subsequent normal SCT (b30 mmol/L).
Parental carrier testing found that his
mother is an F508del carrier. Family
history was reviewed and was
signiﬁcant for a maternal uncle with
recurrent pancreatitis. With knowledge
of a familial CFTR variant and possibly
related disease, this uncle underwent
evaluation where SCT was 70 mmol/L
and variant analysis identiﬁed F508del
and R117H 7 T/9 T, establishing the
diagnosis of CF. Insight was provided for
another uncle with infertility. The same
F508del and R117H 7 T/9 T genotype
was conﬁrmed, as well as CBAVD, with
SCT of 29 mmol/L. In the absence of
other symptoms, a CFTR-RD diagnosis
was established. This genetic counseling
case demonstrates variable expression
of the genotype within the family and
the medical utility of obtaining family
history.
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CFTR variants have been previously classiﬁed according tomolecular
impact. Class I variants result in no useful transcription of protein, in-
cluding: variants resulting in a premature stop codon (nonsense vari-
ants, ending in X in legacy nomenclature); variants affecting canonical
splice sites (+1 and−1 positions adjacent to exons); and variants lead-
ing to large deletions. Class II variants result in transcription of full-
length but abnormal protein that is misfolded or incorrectly trafﬁcked
to the cell membrane. For class III variants, full-length protein is tran-
scribed and correctly located but does not function. Class IV variants
produce a protein that reaches the cell surface but has decreased chlo-
ride conductance. Class V variants produce a reduced quantity of func-
tional CFTR protein, often due to mis-splicing, and Class VI variants
produce a less stable CFTR molecule (Fig. 1). Recently, it has been sug-
gested that Class I variants are divided into those with a premature
stop codon, which may be amenable to read-through correction by
small molecules, and those with no CFTR production (deletions or
large duplications; suggested terms for this group are Class VII or Class
Zero) which are likely not amenable to small molecule correction [9].
Patients and families are increasingly interested in their variant in-
formation and classiﬁcation. Drug development has fostered a tendency
to describe variants by their potential response to small molecule ther-
apies. Class III variants are widely referred to as gating variants, which
are expected to respond to a potentiator such as ivacaftor. Other classes
have been grouped as either minimal function (class I-II) or residualPlease cite this article as: K.E. Foil, A. Powers, K.S. Raraigh, et al., The increa
Fibrosis, https://doi.org/10.1016/j.jcf.2018.11.014function (class IV-VI) (Fig. 1) [10], although this oversimpliﬁes a com-
plex situation and varied response to new therapies has demonstrated
that some variants may straddle a number of classes.
The challenge of characterizing numerous variants underscores the
importance of understanding their molecular impact. Genetic coun-
selors can advise families on functional classes and whether therapies
are available.
4. Diagnostic dilemmas
Diagnostic dilemmas are frustrating for patients and providers.
While genetic testing has improved diagnostic ability, it requires that
a) two CFTR variants are identiﬁed in trans, and b) both variants are
known to cause CF. Over 2000 variants have been identiﬁed in CFTR
(http://www.genet.sickkids.on.ca/cftr/), but only 336 have been rigor-
ously studied and deﬁned as CF-causing [5]. Interpretation of rare and
variable consequence variants remains challenging. Genetic counselors
work alongside providers to deﬁne diagnoses in uncertain situations
and are trained to synthesize available information, provide educated
interpretation of some variants with unknown liability, and provide in-
sight for well-described variants with variable consequences (Case 2).
Intermediate SCT results (30–59 mmol/L), symptoms not unique to
CF, or fewer than two CF-causing variants pose clinical challenges. Ge-
netic counselors are adept in considering other etiologies if CF is not
conﬁrmed and symptoms overlap other conditions. The most
commonly-discussed differential diagnoses are primary ciliary dyskine-
sia, non-CF bronchiectasis, pseudohypoaldosteronism, and
Shwachman-Diamond syndrome. In the absence of an alternative diag-
nosis, individuals with unclear presentations are difﬁcult to diagnose or
dismiss from CF care. Uncertainty can have a signiﬁcant psychological
impact on a patient or family and genetic counselors can provide the
necessary emotional support [18]. Furthermore, genetic counselors
can contribute to ongoing care of individuals with unusual presenta-
tions of CF, CFTR-RD, or CRMS/CFSPID by regularly reviewing databases
such as CFTR2 for new variant interpretations and clinical information.
5. Prenatal
American College of Obstetrics and Gynecology (ACOG) guidelines
(2011) recommend that CF carrier screening be offered to all women
who are pregnant or considering pregnancy [19]. A common variantsing challenge of genetic counseling for cystic ﬁbrosis, Journal of Cystic
Classification of CFTR variants
Little to no
CFTR protein
Class III*
QUANTITY
of CFTR protein at the 
cell surface is affected
Minimal function variants Residual function variants
FUNCTION 
of CFTR protein at the 
cell surface is affected
NORMAL
CFTR protein 
quantity and function
Some CFTR 
protein
Gating defect
Conductance 
defect
Class IVClass VClass VI
Class I
Class II
Cl- Cl-
Cl-
Cl-
Cl- Cl-Cl- Cl- Cl
- Cl- Cl-Cl-
Cl-
Cl-
Cl-
Cl- Cl- Cl- Cl
-
Cl-
Cl- Cl-
Fig. 1. The schematic represents the amount of CFTR protein in the cell membrane and the impact on function (illustrated by the movement of chloride ions (Cl-) out of the cell).
Classiﬁcation of CFTR mutations: minimal function (class I-II) and residual function (class IV-VI) [10–17]. *Class III mutations are known as gating variants because they may respond
to a potentiator such as ivacaftor. Examples of variants for each class (HGVS name [legacy name]): Class I: c.1624GNT [G542X]; Class II: c.1521_1523delCTT [F508del]; Class III:
c.1652GNA [G551D]; Class IV: c.350GNA [R117H]; Class V: c.3718-2477CNT [3849+10kbCNT]; Class VI: c.120del123 [252del123].
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tice varies. The concept of residual risk after carrier screening should be
discussed, as many patients assume negative screening eliminates car-
rier risk. However, screening is not always accompanied by genetic
counseling, particularly in the setting of negative results. Sensitivity
for the common 23-variant panel in the US varies by ethnicity, ranging
from ~49% in Asians to ~94% in Ashkenazi Jews [20]. Without appropri-
ate counseling, it can be surprising and distressing if an affected child is
born after negative carrier screening. Discrepancies may also exist be-
tween carrier screening panels and those used in NBS; some infants
may be found by NBS to carry a variant not interrogated by parental
screening.
A study of CF patients' attitudes toward carrier screening found that
N80% supported preconception carrier screening [21]; still, the greatest
uptake of carrier screening is among pregnant couples, often through
their obstetrician. Approximately 69% of couples screened through
population-based carrier screening in Australia were pregnant at the
time of testing [21,22].
When a carrier is identiﬁed, partner testing options include a variant
panel or CFTR sequencing. Counseling should include discussion of the
beneﬁts and limitations of each technology, as well as costs, turnaround
time, and the possibility of identifying variants of uncertain signiﬁcance,
if reported by the laboratory. Testing bothmembers of a couple concur-
rently with a panel provides results quickly; however some may seek
additional testing if one partner has a positive ﬁnding. For example,
the residual risk to be a carrier after a negative 23-variant panel is ~1
in 200 for a Caucasian, non-Jewish individual. If his/her partner is a car-
rier, the residual risk to have an affected child is 1 in 800. By contrast,
negative sequencing reduces the same patient's carrier risk to ~1 in
2700, resulting in a reproductive risk of 1 in 10,800. While some pro-
viders offer high sensitivity variant panels or sequencing for partner
testing, advanced testingmay not be covered by insurance, and the pos-
sibility of discovering a variant of uncertain signiﬁcance should be
discussed, if applicable.
Carrier screening is available through numerous laboratories. Next
generation sequencing (NGS) allows hundreds of genes to be sequenced
simultaneously for carrier screening, often at the same out-of-pocket
cost as CFTR panel testing alone. Known as expanded carrier screening,Please cite this article as: K.E. Foil, A. Powers, K.S. Raraigh, et al., The increa
Fibrosis, https://doi.org/10.1016/j.jcf.2018.11.014CF carrier screening in this context poses challenges. Typically, ex-
panded carrier screening panels do not report variants of uncertain sig-
niﬁcance (only pathogenic or likely pathogenic variants) and still
require a discussion of residual risk. Genetic counselors are tasked
with explaining screening that may include hundreds of conditions,
making it difﬁcult to describe each in detail. As a result, patients are sur-
prised to receive positive results when there is no family history of the
condition or they did not have full knowledge of conditions tested [23].
Prenatal concern for CF may also arise due to hyperechoic bowel on
prenatal ultrasound. Among many etiologies, fetal hyperechoic bowel
can be caused by altered meconium consistency in the small intestine
resulting from pancreatic enzyme secretion abnormalities. Hyperechoic
bowel has been reported in 50–78% of fetuses with known CF, and the
ﬁnding of hyperechoic bowel in a fetus without previously known CF
risk is associated with a 0.8–13.3% chance for CF, depending on parental
ethnicity and other factors [24]. Therefore, this ﬁnding should prompt
discussion of CF and parental carrier screening if not already performed.
Most carrier couples have no family history of CF, no prior knowl-
edge of the condition, and require substantial education. A study of pre-
natal genetic counselors' preparedness to discuss CF with carrier
couples found “the majority of counselors would ‘deﬁnitely’ discuss
physical health (94.2%), life expectancy (86.4%) and treatment burden
(70.8%), while less than a quarter would ‘deﬁnitely’ discuss psychologi-
cal and emotional health (22.7%) or social functioning and personal goal
fulﬁllment (24%).” Genetic counselors in prenatal settings often did not
feel knowledgeable discussing newer CF treatments and expressed the
need to refer to a CF specialist [25].
Preimplantation genetic diagnosis (PGD/PIGD) is an option for car-
rier couples; it involves embryo biopsy and genetic testing for known
parental variants after embryos are achieved using in vitro fertilization.
Prospective parents may choose embryo transfer of only those without
the disease-causing genotype. European Society of Human Reproduc-
tion and Embryology (ESHRE) PGD consortium data show that CF ac-
counts for ~10% of indications for monogenic disorders [26]. Genetic
counselors and CF specialists are often asked in the preconception or
prenatal timeframe to predict phenotype based on genotype. Registries
and databases aid in this task, yet couples should be informed of the
range of outcomes associated with any genotype [26]. Carrier couplessing challenge of genetic counseling for cystic ﬁbrosis, Journal of Cystic
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current pregnancy, invasive prenatal diagnostic testing and possibly
pregnancy termination. Appropriate counseling by a clinician with CF
expertise may help avoid termination of pregnancy when a fetus has a
non CF-causing variant or variant associated with mild disease. Some
countries restrict which conditions or variants are acceptable for PGD;
this option may not be available for some families carrying a variant of
varying clinical consequence [27].
6. Newborn screening
Newborn screening for CF is a successful public health strategy for
early recognition of affected infants, facilitating proactive treatment
[28]. This strategy has been adopted by most countries in which the
prevalence of CF is high. All programs utilize measurement of
immuno-reactive trypsinogen (IRT) from a dried bloodspot sample col-
lected in the ﬁrst week of life, followed by a second tier of testing, which
often includes molecular analysis for CFTR variants (Table 4) [29]. Inclu-
sion of DNA testing improves speciﬁcity and timeliness, particularly
when two variants are identiﬁed. DNA testing is generally performed
on the initial sample with variant panels targeted at the population
being screened. This streamlined protocol is especially beneﬁcial in re-
gions where geography or resources limit collection of a second dried
bloodspot sample. Incorporation of DNA testing increases recognition
of CF carriers, as these infants have higher IRT values [30]. In most pro-
grams, a normal SCT (b30 mmol/L) is used to report that CF is unlikely.
In some programs, a repeat IRT measurement at day-of-life 10–21 is
used to avoid the need for SCT if the result is normal.
Some programs have attempted to reduce carrier recognition and
improve positive predictive value (PPV) using pancreatitis associated
protein (PAP) and/or extended gene analysis through CFTR sequencing
[31]. Extended gene analysis as a third-tier test signiﬁcantly improves
PPV but increases detection of variants of unknown signiﬁcance. In
these cases, SCT is important to evaluate physiological evidence of CF;
however, if the result is normal or intermediate, uncertainty remains.
Because variable penetrance of some CFTR variants is well-recognized,
a portion of these well infants are at risk for CFTR-RD or CF later in
life. Infants with an inconclusive diagnostic evaluation after positive
NBS have been designated CFTR-related metabolic syndrome (CRMS)
in the US and CF screen positive, inconclusive diagnosis (CFSPID) in
other countries. It is important to appreciate that the risk for disease
in these otherwise well infants is difﬁcult to quantify.
Genetic counseling for families of an infant with CRMS/CFSPID
should include: a) carrier status education; b) family planning discus-
sion; c) documentation of family history; and d) ensuring extensive
genotyping for diagnostic purposes, particularly in the case of an inter-
mediate SCT (30–59mmol/L). In certain situations, it is unclear if an in-
fant is a carrier or has CRMS/CFSPID and parental testing is necessary to
determine if an infant's variants are in cis or trans. In the situation of aTable 4
Description of different models of CF newborn screening [30–32,35,38,40–49].
Model Sensitivity PPV Pros
IRT/IRT 76% 5–16% May be appropriate in countries with a low incidence
IRT/PAP 80% 5–10% Lowest detection of carriers; No second sample neede
IRT/PAP/
DNA/Seq
95% 88% Highest PPV and speciﬁcity; Low carrier detection; No
needed
IRT/DNA/IRT 97% 65% Very high speciﬁcity
IRT/IRT/DNA 96% 27% High speciﬁcity
IRT/DNA 95–98% 9% Most commonly used protocol; Improves timeliness;
needed
IRT/DNA/Seq 92% 34% High speciﬁcity; Improves detection in ethnically dive
No second sample needed; Lowest number of referral
Legend: IRT- Immuno-reactive trypsinogen; PAP- pancreatitis associated protein; DNA refers to
which can use Sanger or next-generation sequencing
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than two CF-causing variants in trans, CF is unlikely [32]. Infants with
an intermediate SCT result have higher risk of being reclassiﬁed as CF,
but the majority remain well [33]. A study of infants with CFSPID from
Canada and Italy demonstrated 11% reclassiﬁcation to CF due to an in-
crease in SCT to N60 mmol/L and/or change in variant classiﬁcation on
the CFTR2 website [4]. A California study of children with CRMS with
(TG)13-5 T and a CF-causing variant found 38% reclassiﬁcation to CF
in the ﬁrst 8 years of life based on SCT and clinical presentation [34].
An unknown percentage of infants with CRMS/CFSPIDmay be at risk
for future CFTR-RD, which describes a single-organ condition that re-
lates to CFTR dysfunction but does not meet CF diagnostic criteria [35].
This classiﬁcation typically includes congenital bilateral absence of the
vas deferens (CBAVD) in males, pancreatitis, or bronchiectasis. There
is no doubt that infants with CRMS/CFSPID have an increased a priori
risk of CFTR-RD, though risk is difﬁcult to quantify.
When an infant with CRMS/CFSPID develops CF-related symptoms
such as chronic cough, there is a tendency to diagnose initially with
CFTR-RD, rather than CF [36]. While understandable, these children
still have some risk tomeet CF diagnostic criteria later in life. It is impor-
tant that infants in this situation receive appropriate CF care and that
families receive relevant information. Because phenotype, symptoms,
or diagnoses may change years after initial counseling, written mate-
rials are helpful for parents [37].
Genetic counselors have a number of roles within NBS programs. For
infants recognized as carriers (false positive NBS), a genetic counselor
may be the only healthcare professional outside of primary care to ad-
dress this result. The genetic counselor provides parents with informa-
tion on CF carrier testing, risks for future pregnancies, and cascade
screening for family members. Support and education by a genetic
counselor reduce parental long-term stress [38]. It is also important to
address ownership of genetic information and how and when families
should relay genetic results to their child. There is limited research
and no consensus guideline on disclosure of carrier status to children;
one study of Fragile X carriers suggested that disclosure occur during
teenage years [39]. While more research is needed, a genetic counselor
is well-poised to work through the process with a family.
For infants diagnosed with CF after NBS, genetic counselor involve-
ment may occur after parental adjustment. In other cases, the genetic
counselor facilitates diagnostic understanding or delivers the diagnosis.
If a genetic counselor is not involved upfront, a referral should be pro-
vided, as genetic counselors provide parents with support and impor-
tant information about recurrence and familial risk. Some genetic
counselors work closely with or within the CF team, which has advan-
tages: staying connected to the ever-changing CF world and having in-
depth knowledge of CFTR variants and therapies. In other services, the
genetic counselor is separate from the CF team. This offers other advan-
tages: the family may feel more comfortable discussing reproductive
decisions with a professional independent of their CF team [38,39].Cons
of F508del Low speciﬁcity (high false positive rates); Requires collection
of second sample
d Low speciﬁcity (high false positive rates)
second sample More costly; Identiﬁes variants of uncertain signiﬁcance
(increased CRMS/CFSPID)
Requires second sample
Requires second sample
No second sample High carrier detection; Low speciﬁcity (high false positives);
Results the highest number of referrals for sweat testing
rse populations;
s for sweat testing
Increases the detection of carriers and CRMS/CFSPID
a CFTR variant panel (variants tested differ among programs); Seq - CFTR gene sequencing,
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Genetic testing is a critical step in obtaining complete diagnostic
information for an infant or child with CF, which guides treatment at
increasingly earlier ages. Genetic counselors advise on test selection
and explain inheritance and results to parents of a newly diagnosed
child, and later to the child his- or herself.
Children with CF have varied genetic counseling needs in different
developmental stages. The question, “Whydo I have CF?” is an opportu-
nity for age-appropriate explanations about genes and inheritance. Ad-
olescents may be exposed to CF genetics through their studies in school
and have corresponding questions. Anticipatory discussions of the
child's preference for disclosure of diagnosis to classmates during school
years may be warranted, as this topic can be sensitive and preferences
differ. Teens with CF should have staged education on fertility, recur-
rence risk, assisted reproductive technologies (ART), and partner carrier
testing, in addition to routine sexual health education. Studies indicate
that parents and patients wish to have conversations about sexual and
reproductive health with healthcare providers by age 14, which is
often earlier than reported experiences [50,51]. It is important to con-
sider preferences of parents and patients in relaying this information;
incorporating genetic counseling early in this process provides a robust
framework on which education from the CF team can be placed.
A CF diagnosis has implications for siblings and family planning.
Genetic counseling at regular intervals allows for timely, accurate,
supportive, and non-directive information on recurrence risk and repro-
ductive options. Facilitation and afﬁrmation of parental decision-
making are vital in these situations.
United States Cystic Fibrosis Foundation (CFF) guidelines recom-
mend that “families of infants diagnosed with CF should receive appro-
priate education at the ﬁrst diagnostic visit, and genetic counseling
should be provided [3].” A SCT should be performed on ﬁrst-degree
siblings and on half-siblings with CF symptoms [3,52]. Approaches to
sibling testing vary; most clinicians recommend a SCT but some opt
for familial variant testing instead or in addition [53]. In the event of a
negative SCT, the sibling has a 2/3 (66%) chance of being a carrier. It is
important to convey that SCT does not determine carrier status. Carrier
testing in children is not supported by many professional organizations
[54]. Still, many parents request sibling carrier testing and can be frus-
trated if refused, so careful counseling is required [55,56]. If carrier test-
ing is performed, pre- and post-test genetic counseling is essential.
When the proband's CF genotype is associated with variable SCT values
b60 mmol/L (e.g. R117H), special consideration should be given to the
diagnostic capabilities and limitations of both SCT and familial variant
testing.
8. Adult
Althoughmost CF patients are diagnosed as children, more than half
of individuals living with CF are adults. Increasing life expectancy and
better health allow many adults with CF to fully engage in careers,
hobbies, family, and enjoy a high quality of life [57]. Educational and
support needs throughout adulthood encompass sexual health
and family planning, emotional and relational issues, and wellness
strategies.
Education about reproductive options helps adults with CF achieve
relational and family goals. Informed decision-making and exploring
risks and beneﬁts are central to the process of genetic counseling. Before
conception planning, adults with CF should understand their physio-
logic ability to have children, risk for disease recurrence (50% if partner
is a carrier; partner carrier testing should be offered), and review
personal goals and health status. A partner's negative carrier screen sig-
niﬁcantly reduces risk of an affected child, and residual risk should be
addressed. Burdens of treatment time and cost, reality of caring for
self and child, and possible death of a parent before a child is grown
may affect family planning. Decisions regarding whether and how toPlease cite this article as: K.E. Foil, A. Powers, K.S. Raraigh, et al., The increa
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ART with or without PGD, gamete donation or surrogacy, adoption, or
the choice not to have children. Regardless of parenthood plans, adults
should be informed and have discussions about sexual health in CF
with a knowledgeable team member.
Over 95% of males with CF are infertile due to CBAVD; however, via-
ble sperm can be retrieved from N90% of infertilemenwith CF for use in
IVF [58]. Most females may achieve natural pregnancy, though thicker
cervical mucosa or poor nutritional status can impair fertility. Genetic
counselors are familiarwith fertility processes and reproductive options
and can guide the education and decision-making process, including
necessary specialist referrals.
As more females with CF become pregnant, care teams should dis-
cuss pregnancy planning and safety in CF, addressing questions about
effects on short- and long-term health. Factors to consider include: ma-
ternal lung function, nutritional and pancreatic sufﬁciency status, CF-
related diabetes, maternal risks for increased exacerbation frequency
and gestational hypertension, and fetal risk for preterm birth and low
birth weight. Despite these risks, maternal outcomes for women with
CF are generally good. No difference has been shown between 10-year
survival rates for femaleswith CFwho carried a pregnancy andmatched
controls with CF who did not [59]. More recently, a small case-control
study showed no effect of pregnancy on nutritional outcomes, changes
in lung function, or exacerbation rates during a 4.5 year period [60].
Individuals diagnosed as adults (~4–5% of CF patients) are a unique
cohort. Improved genetic testing, lower threshold of normal SCT values
(b30 mmol/L), and recognition of a broader clinical spectrum allow as-
certainment of older individuals with milder or later onset symptoms,
often related to milder CFTR variants. Currently, those diagnosed in
adulthood were typically born before CF NBS and may represent an
age-advanced CRMS/CFSPID cohort that is well during childhood with
later conversion. These individuals beneﬁt from genetic counseling as
well, addressing subjects classically discussed in a childhood diagnosis.
Mental health is now recognized as a critical issue in CF, with 2016
CFF guidelines recommending that all adolescents (12+) and adults
with CF be screened for symptoms of depression and anxiety [61]. Ge-
netic counselors have training in psychosocial assessment and counsel-
ing and can assist with annual screening and wellness needs.
9. CFTR therapies
The year 2012 marked a signiﬁcant milestone in CF care, with ap-
proval in the US of a molecular therapy, ivacaftor, that corrects the de-
fective CFTR protein bearing the variant c.1652GNA [G551D] [62], with
approval in other countries soon after. Clinical trials of ivacaftor demon-
strated immediate, signiﬁcant, and sustained clinical beneﬁt with in-
creased FEV1, decreased sweat chloride, and decreased pulmonary
exacerbation frequency [63–66].While knowledge of an individual's ge-
notype was previously helpful for diagnosis, prognosis, and research
purposes, it became essential for ensuring optimal treatment. Addi-
tional compounds have received approval in some countries
(lumacaftor-ivacaftor and tezacaftor-ivacaftor) and are available for pa-
tients with over 40 speciﬁc variants. Ongoing clinical trials are evaluat-
ing long-term effects of modulator treatments and efﬁcacy for other
genotypes, underscoring the importance of correct variant identiﬁca-
tion and interpretation in all patients. Research continues to develop
compounds to treat a greater number of CFTR variants, although
F508del remains the prime focus, as nearly 90% of people with CF
have at least one copy of this variant.
A small percentage of individuals carry two variants that result in no
CFTR protein production (nonsense, canonical splice, exon deletions,
etc.). The early promise of read-through agents, such as ataluren, that
prevent use of premature termination codons, has not been realized
and the ataluren research programhas notmoved forward [67]. At pres-
ent, there are no molecular therapies to address these variants and at-
tention has moved to alternative strategies such as gene replacementsing challenge of genetic counseling for cystic ﬁbrosis, Journal of Cystic
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explored for some CFTR variants [68]. This technique shows promise
in the laboratory but has not yet progressed to clinical trials. Additional
gene- or RNA-targeted therapies include antisense oligonucleotides,
some of which are in early-stage clinical trials, and gene replacement
therapy using liposomes, which has been investigated in large clinical
trials with some minimal evidence of efﬁcacy [69]. These approaches
offer some promise to correct the underlying genetic defect in people
with CF, but are not yet at a stage that impacts genetic counseling
advice.
Genetic counselors can assist providers and patients in identifying
personalized treatment options and research studies. In the US,
the role of a CF genetic counselor may include identifying appropriate
molecular treatment or clinical trials for an individual, explaining the
molecular mechanism of treatments, or discussing potential effects of
treatments upon fertility or pregnancy, though these duties vary
among clinics. For example, genetic counselors in CF clinics or
maternal-fetal medicine practice will highlight complications such as
the reduced effectiveness of hormonal contraception with lumacaftor-
ivacaftor, and potential teratogenic effects of other CF treatments.
Coupled with expertise in family planning options, a genetic counselor
can help balance modulator eligibility with personal needs and goals.
Counseling on life expectancy for those with CF now needs to take
into account the emergence of new therapies. Genetic counseling in
the prenatal setting for someone carrying a variant such as G551D
with an approved and effective molecular therapy is different than for
someone who carries a nonsense variant for which no treatment is
available.10. Professional issues
Genetic counselor involvement differs among CF centers, with some
genetic counselors also working with patient registry data, study coor-
dination, and group education. Genetic counselors have unique
perspectives of viewing the patient, immediate, and extended family
as a whole. Patient conﬁdentiality is emphasized; yet in heritable diag-
noses, patients should be provided with information about themode of
inheritance, associated risks, and appropriate screening and interven-
tion options for family members [70]. Genetic counselors are skilled at
assessing and discussing familial risk, ensuring the patient is equipped
to share recommendations with relatives (e.g. through a family share
letter).
CF centers that have a genetic counselor in clinic ﬁnd it beneﬁcial to
the team and patients [71]. Others cite cost, logistics, and availability as
barriers to incorporating a genetic counselor. Convenient and timely ac-
cess to genetic counselors can be challenging, as a relative shortage of
genetic counselors exists compared to clinical need. National genetic
counselor organizations have ongoing efforts to examine workforce is-
sues, particularly in direct patient care [72]. In the US, the genetic coun-
selor workforce has grown 88–100% in the past 10 years, with
continued projected growth of 72–100% in the next decade [6,73].
While this trend is encouraging, the current and projected increase in
workforce may still not be enough to meet ideal clinical stafﬁng needs.
In the absence of an in-person genetic counselor, clinicians may con-
sider a variety of other ways to deliver pertinent information. Telemed-
icine through hospital-based or contracted genetic counselors is
becoming more widely available in some areas [40,41]. For example,
telephone genetic counseling is offered by the California NBS program.
Having this resource is better than none, but consumer-driven utiliza-
tion of this service has been only 12% [28]. CF providers may also ﬁnd
it necessary to provide genetics education and basic counseling in CF
clinic, including explanation of inheritance, the patient's genotype,
and discussion of recurrence risk. In these situations especially, having
patient materials to distribute may be helpful. Because genetics and ge-
netic counseling can be quite complex, it is important that patients andPlease cite this article as: K.E. Foil, A. Powers, K.S. Raraigh, et al., The increa
Fibrosis, https://doi.org/10.1016/j.jcf.2018.11.014families have an opportunity to engagewith a genetic counselor, partic-
ularly one who specializes in CF.
Inconsistent billing and reimbursement for genetic counselor ser-
vices is sometimes also an issue in some parts of the US and other coun-
tries. In the US, despite American Medical Association (AMA) approval
of the billing code for “medical genetics and genetic counseling ser-
vices,” reimbursement varies with factors such as credentialing and
state licensure [74]. Federal advocacy efforts aim to “improve access to
quality genetic counseling and ensure the genetic counseling profession
is a recognized and integral part of the healthcare system” [6]. It is hope-
ful that with improved reimbursement, CF patients and families will
have increased genetic counselor access over time.
11. Conclusion
Genetic counselors understand the implications of genetic results
and can translate these concepts to people with CF, their families, and
care team. This spans from helping patients and families understand
their diagnosis to processing complex decisions; genetic counselor sup-
port and expertise are needed throughout the increasing lifespan. Hav-
ing dual psychosocial and medical roles, genetic counselors provide an
important bridge between scientiﬁc advancement and real-world appli-
cation to improve CF lives and care.
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